DePuy ASR Hip Recall Could Yield Unprecedented Damages

Ryan Green | June 7th, 2011 | Posted in Depuy Hip Recall

By the time that Johnson & Johnson ordered a voluntary DePuy hip implant recall in 2010, nearly 100,00 people worldwide had already received the defective orthopedic implant. For many patients who experienced side effects such as device dislocation, metal poisoning, or revision surgery, a lawsuit is their only compensatory recourse.

British study leads to DePuy ASR Hip Recall

Years of reports from patients who suffered excruciating pain as a result of DePuy hip complications were finally confirmed by hard data in 2010, when a study by the professional British Orthopaedic Association revealed premature hip failure in almost 15% of DePuy ASR model hip implants.

Intended to last for 15 years and to support patients with active lifestyles, the artificial hip replacement system was found in many cases to fail within two years of surgery. The recall that followed soon after the U.K. findings were published included the DePuy ASR Hip Resurfacing System, which had been used on U.S. patients without having ever been approved by the FDA for sale in the first place.

Other reported hip complications that contributed to the recall include inflammation, excessive joint stiffness, difficulty walking, bone loss or damage, and even loss of hearing or impaired vision due to metallosis. Most of these hip complications ultimately resulted from the implant’s failure to naturally fuse to the patient’s bone.

No indication of DePuy Pinnacle hip recall

The DePuy Pinnacle hip model has also been the target of many lawsuits, though as yet it has avoided recall. While the DePuy ASR hip is constructed solely of metal components, the Pinnacle model is available in a variety of ball-in-socket arrangements, including metal-on-metal, metal-on-ceramic, and metal-on-polyethylene.

DePuy hip lawsuit consolidation and settlement fund

Both DePuy ASR hip lawsuits and DePuy Pinnacle hip lawsuits have been consolidated, in separate federal panel decisions, into multidistrict legislation (MDL) for the purposes of pre-trial proceedings, including shared discoveries and depositions.

David Floyd, the ex-president of DePuy Orthopaedics, resigned in March of this year, shortly after parent company Johnson & Johnson revealed that it was setting aside close to $1 billion for expected settlement payouts for lawsuits. As the number of total DePuy hip lawsuit filings increases, the sum amount of damages is expected to grow substantially.

Invalid tag specified, please contact administrator.